Should I buy or sell Zydus Lifesciences?

The average broker rating on Zydus Lifesciences is Hold. The breakup of analyst rating is given below - 2 analysts have given a strong sell rating 3 analysts have given a sell rating 10 analysts have given a hold rating 9 analysts have given a buy rating 3 analysts have given a strong buy rating

Is Zydus Lifesciences a good stock to invest in?

Zydus Lifesciences can be analyzed on the following key metrics - TTM P/E: 21.59 Sector P/E: 26.85 Dividend Yield: 0.34% D/E ratio: -

Zydus Lifesciences Share Price

Sector: Biotechnology & Drugs

Powered by

891.30 +5.85 (0.66%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 881.00

Today’s High 894.20

52 Week Low 797.05

52 Week High 1323.90

Key Metrics

Market Cap (In Cr) 89645.14
Beta 0.55
Div. Yield (%) 0.34
P/B 4.49
TTM P/E 21.59
Peg Ratio 0.95
Sector P/E 26.85
Open Price 886
Prev Close 885.45

View All Metrics

Zydus Lifesciences Analysis

Price Analysis

1 Week

0.61%
3 Months

-8.72%
6 Month

-11.79%
YTD

-8.86%
1 Year

-10.36%

Risk Meter

28% Low risk
28% Moderate risk
28% Balanced Risk
28% High risk
28% Extreme risk

Recos

Strong Sell
Sell
Hold
Buy
Strong Buy

Analysts' Views

Ratings
Current
1 W Ago
1 M Ago
3 M Ago

Strong Buy
3
3
3
3

Buy
9
9
9
10

Hold
10
10
10
8

Sell
3
3
3
4

Strong Sell
2
2
2
3

Total
27
27
27
28

Zydus Lifesciences News

Stocks to watch: Reliance Industries, IDFC First Bank, IRFC, Adani Green among shares in focus today.

Premium

Stocks to watch: RIL, IRFC, IDFC First, Adani Green among shares in focus today

1 min read . 28 Apr 2025

Lupin, Zydus Life shares slide up to 7.5% after US Court blocks generic version of Myrbetriq over patent infringement

Premium

Lupin, Zydus Life fall as US court blocks generic Myrbetriq over patent row

2 min read . 16 Apr 2025

Opening Bell - Stocks to buy or sell for short-term in F&O segment: Jay Thakkar of ICICI Securities recommends LIC Housing Finance Futures, Zydus Lifesciences Futures, and IDFC First Bank Futures.

Premium

Jay Thakkar of ICICI Sec suggests THESE shares to buy or sell in F&O segment

5 min read . 16 Apr 2025

Of India's pharma exports of $27.9 billion in FY24, $8.7 billion or 31% were to the US. Photo: Dhiraj Singh/Bloomberg

Premium

Indian pharma companies escape Trump’s reciprocal tariffs, for now

4 min read . 03 Apr 2025

View More News

Zydus Lifesciences Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2024

Total Revenue
19547.4

Selling/ General/ Admin Expenses Total
6319.1

Depreciation/ Amortization
764.1

Other Operating Expenses Total
884

Total Operating Expense
15025.9

Operating Income
4521.5

Net Income Before Taxes
4808.9

Net Income
3859.5

Diluted Normalized EPS
37.92

Period
2023

Total Revenue
17237.4

Selling/ General/ Admin Expenses Total
6263.3

Depreciation/ Amortization
722.7

Other Operating Expenses Total
342.3

Total Operating Expense
14988.8

Operating Income
2248.6

Net Income Before Taxes
2589.7

Net Income
1960.3

Diluted Normalized EPS
23.79

Period
2022

Total Revenue
15109.9

Selling/ General/ Admin Expenses Total
5385.9

Depreciation/ Amortization
713

Other Operating Expenses Total
288.4

Total Operating Expense
12523.1

Operating Income
2586.8

Net Income Before Taxes
2838.1

Net Income
4487.3

Diluted Normalized EPS
21.01

Period
2021

Total Revenue
14403.5

Selling/ General/ Admin Expenses Total
5254.6

Depreciation/ Amortization
669.6

Other Operating Expenses Total
301

Total Operating Expense
11873

Operating Income
2530.5

Net Income Before Taxes
2399.2

Net Income
2133.6

Diluted Normalized EPS
23.38

Period
2020

Total Revenue
14253.1

Selling/ General/ Admin Expenses Total
5142.8

Depreciation/ Amortization
696.5

Other Operating Expenses Total
804.3

Total Operating Expense
12515.1

Operating Income
1738

Net Income Before Taxes
1495.4

Net Income
1176.6

Diluted Normalized EPS
14.4

Period
2019

Total Revenue
13165.6

Selling/ General/ Admin Expenses Total
4287.6

Depreciation/ Amortization
598.6

Other Operating Expenses Total
592.2

Total Operating Expense
10783.4

Operating Income
2382.2

Net Income Before Taxes
2382.1

Net Income
1848.8

Diluted Normalized EPS
18.12

Period
2018

Total Revenue
11954.4

Selling/ General/ Admin Expenses Total
3850

Depreciation/ Amortization
538.8

Other Operating Expenses Total
467

Total Operating Expense
9643.4

Operating Income
2311

Net Income Before Taxes
2330.8

Net Income
1775.8

Diluted Normalized EPS
17.65

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Zydus Lifesciences Technical

Moving Average SMA

5 Day881.21
10 Day868.33
20 Day866.79

50 Day885.83
100 Day930.19
300 Day1010.24

Zydus Lifesciences Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Dr Reddys Laboratories
1172.5
-10.4
-0.88
1420.2
1025.9
97930.52

Lupin
2081
23.2
1.13
2403.45
1493.75
94923.54

Zydus Lifesciences
891.3
5.85
0.66
1323.9
797.05
89645.14

Abbott India
30820
67.3
0.22
31900
25260.2
65560.45

Alkem Laboratories
5100
27.2
0.54
6440
4409.9
60827.03

Zydus Lifesciences Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

05-Feb-25
Quarterly Results

12-Nov-24
Quarterly Results

09-Aug-24
Quarterly Results

17-May-24
Audited Results & Final Dividend

09-Feb-24
Quarterly Results & Buy Back of shares

07-Nov-23
Quarterly Results

11-Aug-23
Quarterly Results

18-May-23
Audited Results & Final Dividend

03-Feb-23
Quarterly Results

11-Nov-22
Quarterly Results

Meeting Date
Announced on
Purpose

09-Aug-24
17-May-24
AGM

11-Aug-23
18-May-23
AGM

10-Aug-22
21-May-22
AGM

18-Feb-22
25-Jan-22
EGM

11-Aug-21
27-May-21
AGM

11-Jun-21
18-May-21
EGM

-
20-May-22
Others

-
12-Feb-24
Others

Announced on
Record Date
Ex-Dividend
Dividend Value

17-May-24
26-Jul-24
26-Jul-24
3

18-May-23
28-Jul-23
28-Jul-23
6

20-May-22
29-Jul-22
28-Jul-22
2.5

27-May-21
-
28-Jul-21
3.5

View All

Company Profile

ABOUT Zydus Lifesciences

Industry Biotechnology & Drugs
ISIN INE010B01027
BSE Code 532321
NSE Code ZYDUSLIFE

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

MANAGEMENT

Nitin Parekh Chief Financial Officer
Dhaval Soni Company Secretary, Compliance Officer
Sharvil Patel Managing Director, Executive Director
Ganesh Nayak Executive Director

ZYDUS LIFESCIENCES SUMMARY

Zydus Lifesciences is trading 0.66% upper at Rs 891.30 as compared to its last closing price. Zydus Lifesciences has been trading in the price range of 894.20 & 881.00. Zydus Lifesciences has given -8.86% in this year & 0.61% in the last 5 days.

Zydus Lifesciences has TTM P/E ratio 21.59 as compared to the sector P/E of 26.85. There are 27 analysts who have initiated coverage on Zydus Lifesciences. There are 3 analysts who have given it a strong buy rating & 9 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.

The company posted a net profit of 1023.5 Crores in its last quarter.

Listed peers of Zydus Lifesciences include Dr Reddys Laboratories (-0.88%), Lupin (1.13%), Zydus Lifesciences (0.66%) etc.

Zydus Lifesciences has a 74.99% promoter holding & 25.01% public holding.

FAQs about Zydus Lifesciences

Zydus Lifesciences is trading at 891.30 as on 5 May, 2025 3:29:00 PM. This is 0.66% upper as compared to its previous closing price of 885.45

The market capitalization of Zydus Lifesciences is 89645.14 Cr as on 5 May, 2025 3:29:00 PM.

The average broker rating on Zydus Lifesciences is Hold. The breakup of analyst rating is given below -

2 analysts have given a strong sell rating
3 analysts have given a sell rating
10 analysts have given a hold rating
9 analysts have given a buy rating
3 analysts have given a strong buy rating

The 52 wk high for Zydus Lifesciences is 1323.90 whereas the 52 wk low is 797.05

Zydus Lifesciences can be analyzed on the following key metrics -

TTM P/E: 21.59
Sector P/E: 26.85
Dividend Yield: 0.34%
D/E ratio: -

Zydus Lifesciences reported a net profit of 3859.5 Cr in 2024.

Zydus Lifesciences Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Zydus Lifesciences Share Price

Price Range

Price Range

Key Metrics

Zydus Lifesciences Analysis

Zydus Lifesciences News

Stocks to watch: RIL, IRFC, IDFC First, Adani Green among shares in focus today

Lupin, Zydus Life fall as US court blocks generic Myrbetriq over patent row

Jay Thakkar of ICICI Sec suggests THESE shares to buy or sell in F&O segment

Indian pharma companies escape Trump’s reciprocal tariffs, for now

Zydus Lifesciences Financials

Forecast

Forecast

Forecast

Zydus Lifesciences Technical

Zydus Lifesciences Peers

Zydus Lifesciences Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Zydus Lifesciences

MANAGEMENT

ZYDUS LIFESCIENCES SUMMARY

FAQs about Zydus Lifesciences

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue